Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.
|Original language||English (US)|
|Number of pages||5|
|Journal||Current Opinion in Pharmacology|
|State||Published - Feb 1 2002|
ASJC Scopus subject areas
- Drug Discovery